TMCnet News
Neumedicines Taps David L. Morash as President and Chief Strategy Officer [Health & Beauty Close - Up](Health & Beauty Close - Up Via Acquire Media NewsEdge) Neumedicines reported the appointment of David L. Morash as President and to the newly created position of Chief Strategy Officer, effective immediately. Morash continues to serve on the Company's Board of Directors and retains responsibilities as Chief Financial Officer. Neumedicines founder Lena A. Basile, Ph.D., J.D., continues as Chief Executive Officer and Chair of the Board. "This is an exceedingly exciting time at Neumedicines as we prepare for multiple clinical studies to evaluate HemaMax's (recombinant human interleukin-12 (rHuIL-12)) ability to re-ignite the compromised immune systems of patients undergoing debilitating and toxic cancer therapies," said Dr. Basile. "Dave has taken a leadership role in advancing our business strategy over the past several years and his new titles better reflect his ongoing responsibilities to our Company." Morash has more than 30 years of senior-level financial and executive experience. Prior to joining Neumedicines, he was Chief Financial Officer of ISE Corp., where he was instrumental in fundraising and in preparations for its initial public offering; and President, Chief Operating Officer and Chief Financial Officer of Axesstel, Inc., a publicly traded company that he helped to take public. He also served as Executive Vice President and Chief Financial Officer of publicly traded Remec; Executive Vice President of Wireless Knowledge, a joint venture between Qualcomm and Microsoft; and Executive Vice President and Chief Financial Officer of Safeskin Corp., a medical device company rated by Forbes as the Best Small Company in the U.S. Neumedicines is a biotherapeutics company. More information and complete details: http://www.neumedicines.com ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. [ Back To TMCnet.com's Homepage ] |